Smith, Salley & Associates Amgen Inc Transaction History

Smith, Salley & Associates

$1.48 Billion
Q3 2024

A detailed history of Smith, Salley & Associates transactions in Amgen Inc stock. As of the latest transaction made, Smith, Salley & Associates holds 14,848 shares of AMGN stock, worth $3.91 Million. This represents 0.32% of its overall portfolio holdings.

Number of Shares

14,848

Previous 14,583 1.82%

Holding current value

$3.91 Million

Previous $4.56 Million 5.0%

% of portfolio

0.32%

Previous 0.34%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 24, 2024	BUY	$309.38 - $337.38 $81,985 - $89,405	265 Added 1.82%	14,848 $4.78 Million
Q2 2024 Jul 29, 2024	BUY	$262.75 - $319.31 $18,655 - $22,671	71 Added 0.49%	14,583 $4.56 Million
Q1 2024 May 02, 2024	SELL	$268.87 - $324.56 $959,328 - $1.16 Million	-3,568 Reduced 19.73%	14,512 $4.13 Million
Q4 2023 Jan 24, 2024	SELL	$255.7 - $288.46 $122,736 - $138,460	-480 Reduced 2.59%	18,080 $5.21 Million
Q3 2023 Oct 27, 2023	SELL	$218.65 - $271.46 $13,556 - $16,830	-62 Reduced 0.33%	18,560 $4.99 Million
Q2 2023 Aug 04, 2023	BUY	$214.27 - $253.37 $899,076 - $1.06 Million	4,196 Added 29.09%	18,622 $4.13 Million
Q1 2023 May 03, 2023	BUY	$225.79 - $275.2 $46,738 - $56,966	207 Added 1.46%	14,426 $3.49 Million
Q4 2022 Feb 03, 2023	SELL	$229.03 - $291.01 $734,499 - $933,269	-3,207 Reduced 18.4%	14,219 $3.73 Million
Q3 2022 Nov 01, 2022	BUY	$224.46 - $253.15 $17,058 - $19,239	76 Added 0.44%	17,426 $3.93 Million
Q2 2022 Aug 01, 2022	BUY	$230.71 - $256.74 $156,882 - $174,583	680 Added 4.08%	17,350 $4.22 Million
Q1 2022 May 10, 2022	BUY	$219.27 - $242.57 $112,485 - $124,438	513 Added 3.18%	16,670 $4.03 Million
Q4 2021 Feb 10, 2022	SELL	$198.88 - $227.6 $91,882 - $105,151	-462 Reduced 2.78%	16,157 $3.63 Million
Q3 2021 Nov 05, 2021	BUY	$212.27 - $248.7 $161,112 - $188,763	759 Added 4.79%	16,619 $3.54 Million
Q2 2021 Aug 09, 2021	SELL	$233.58 - $259.14 $467 - $518	-2 Reduced 0.01%	15,860 $3.87 Million
Q1 2021 Apr 30, 2021	BUY	$221.91 - $258.6 $56,808 - $66,201	256 Added 1.64%	15,862 $3.95 Million
Q4 2020 Jan 28, 2021	SELL	$216.38 - $257.67 $13,199 - $15,717	-61 Reduced 0.39%	15,606 $3.59 Million
Q3 2020 Nov 05, 2020	BUY	$234.65 - $260.95 $28,392 - $31,574	121 Added 0.78%	15,667 $3.98 Million
Q2 2020 Aug 04, 2020	BUY	$197.81 - $242.74 $125,807 - $154,382	636 Added 4.27%	15,546 $3.67 Million
Q1 2020 Apr 24, 2020	SELL	$182.24 - $241.7 $112,624 - $149,370	-618 Reduced 3.98%	14,910 $3.02 Million
Q4 2019 Jan 27, 2020	BUY	$189.21 - $243.2 $19,488 - $25,049	103 Added 0.67%	15,528 $3.74 Million
Q3 2019 Oct 30, 2019	SELL	$174.11 - $208.62 $362,497 - $434,346	-2,082 Reduced 11.89%	15,425 $2.99 Million
Q2 2019 Jul 12, 2019	SELL	$166.7 - $195.41 $124,358 - $145,775	-746 Reduced 4.09%	17,507 $3.23 Million
Q1 2019 May 03, 2019	SELL	$180.87 - $203.88 $40,695 - $45,873	-225 Reduced 1.22%	18,253 $3.47 Million
Q4 2018 Feb 05, 2019	SELL	$178.4 - $208.25 $77,247 - $90,172	-433 Reduced 2.29%	18,478 $3.6 Million
Q3 2018 Nov 06, 2018	SELL	$185.29 - $208.89 $183,992 - $207,427	-993 Reduced 4.99%	18,911 $3.92 Million
Q2 2018 Aug 10, 2018	BUY	$166.05 - $186.51 $36,364 - $40,845	219 Added 1.11%	19,904 $3.67 Million
Q1 2018 May 09, 2018	SELL	$169.43 - $198.0 $18,637 - $21,780	-110 Reduced 0.56%	19,685 $3.36 Million
Q4 2017 Feb 12, 2018	BUY	$168.79 - $188.59 $44,560 - $49,787	264 Added 1.35%	19,795 $3.44 Million
Q3 2017 Nov 02, 2017	BUY	$167.29 - $191.0 $3.27 Million - $3.73 Million	19,531	19,531 $3.64 Million

Others Institutions Holding AMGN

# of Institutions

3,125

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $141B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Smith, Salley & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Smith, Salley & Associates with notifications on news.

Account

Smith, Salley & Associates Amgen Inc Transaction History